Home > News

TaiGen Biotechnology’s Taigexyn was Granted Priority Review by the China Food and Drug Administration

TAIPEI, Taiwan, February 05, 2018 – TaiGen Biotechnology Company, Limited ("TaiGen") announced today that the New Drug Application (NDA) of the intravenous formulation of Taigexyn® (nemonoxacin), was granted priority review from the China Food and Drug Administration (CFDA). The priority review will accelerate the review and approval of the NDA. This is the second priority review granted to TaiGen’s pipeline product in development, the other is furaprevir (TG-2349), the hepatitis C proetease inhibitor in April 2016